Bayer's asundexian first FXIa inhibitor approved by U.S. Food and Drug Administration for secondary stroke risk reduction
November 10, 2026
November 10, 2026
LEVERKUSEN, Germany, Nov. 10 [Category: BizPharmaceuticals] -- Bayer Group, a pharmaceutical and life sciences company, posted the following news release:
* * *
Bayer's asundexian first FXIa inhibitor approved by U.S. Food and Drug Administration for secondary stroke risk reduction
*
Berlin, November 10, 2026 - Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian, 50 mg t . . .
* * *
Bayer's asundexian first FXIa inhibitor approved by U.S. Food and Drug Administration for secondary stroke risk reduction
*
Berlin, November 10, 2026 - Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for asundexian, 50 mg t . . .
